Search results for " type 2"

showing 10 items of 761 documents

Aging modifies receptor expression but not muscular contractile response to angiotensin II in rat jejunum

2022

AbstractThe involvement of renin-angiotensin system in the modulation of gut motility and age-related changes in mRNA expression of angiotensin (Ang II) receptors (ATR) are well accepted. We aimed to characterize, in vitro, the contractile responses induced by Ang II, in jejunum from young (3–6 weeks old) and old rats (≥ 1 year old), to evaluate possible functional differences associated to changes in receptor expression. Mechanical responses to Ang II were examined in vitro as changes in isometric tension. ATR expression was assessed by qRT-PCR. Ang II induced a contractile effect, antagonized by losartan, AT1R antagonist, and increased by PD123319, AT2R antagonist, as well by neural block…

AgingJejunumPhysiologyAngiotensin IIAngiotensin II receptorsIntestinal motilityAnimalsGeneral MedicineReceptor Angiotensin Type 2BiochemistryReceptor Angiotensin Type 1LosartanRats
researchProduct

Lifelong soya consumption in males does not increase lifespan but increases health span under a metabolic stress such as type 2 diabetes mellitus.

2021

Soya consumption can decrease oxidative stress in animal models. Moreover, phytoestrogens such as genistein, present in soya, can mimic some of the beneficial effects of estrogens and are devoid of significant side effects, such as cancer. In this study, we have performed a controlled lifelong study with male OF1 mice that consumed either a soya-free diet or a soya-rich diet. We show that, although we found an increase in the expression and activity of antioxidant enzymes in soya-consuming mice, it did not increase lifespan. We reasoned that the soya diet could not increase lifespan in a very healthy population, but perhaps it could extend health span in stressed animals such as type 2 diab…

Agingmedicine.medical_specialtyAntioxidantGoto Kakizaki ratsmedia_common.quotation_subjectmedicine.medical_treatmentLongevityGenisteinPhytoestrogensDiseasemedicine.disease_causeAntioxidants03 medical and health scienceschemistry.chemical_compoundfluids and secretions0302 clinical medicineStress PhysiologicalInternal medicineMedicineAnimals030304 developmental biologymedia_common2. Zero hunger0303 health sciencesbusiness.industryLongevityfood and beveragesType 2 Diabetes MellitusIsoflavonesAnimal FeedIsoflavones3. Good healthRatsOxidative StressEndocrinologychemistryDiabetes Mellitus Type 2Soya030220 oncology & carcinogenesisAntioxidant enzymesPhytoestrogensSoybeansbusinessOxidative stressDevelopmental BiologyMechanisms of ageing and development
researchProduct

Magnesium and type 2 diabetes.

2015

Type 2 diabetes is frequently associated with both extracellular and intracellular magnesium (Mg) deficits. A chronic latent Mg deficit or an overt clinical hypomagnesemia is common in patients with type 2 diabetes, especially in those with poorly controlled glycemic profiles. Insulin and glucose are important regulators of Mg metabolism. Intracellular Mg plays a key role in regulating insulin action, insulin-mediated-glucose-uptake and vascular tone. Reduced intracellular Mg concentrations result in a defective tyrosine-kinase activity, postreceptorial impairment in insulin action and worsening of insulin resistance in diabetic patients. A low Mg intake and an increased Mg urinary loss app…

Agingmedicine.medical_specialtySettore MED/09 - Medicina InternaDiabetes riskEndocrinology Diabetes and Metabolismmedicine.medical_treatmentType 2 diabetesHypomagnesemiaInsulin resistanceInternal medicineDiabetes mellitusInternal MedicinemedicineMagnesiumEndotheliumAging; Endothelium; Hypertension; Inflammation; Insulin resistance; Magnesium; Metabolic syndrome; Type 2 diabetesGlycemicInflammationbusiness.industryInsulinInsulin resistanceType 2 diabetesMinireviewsmedicine.diseaseMetabolic syndromeEndocrinologyHypertensionMetabolic syndromebusinessWorld journal of diabetes
researchProduct

Role of CB2 receptors and cGMP pathway on the cannabinoid-dependent antiepileptic effects in an in vivo model of partial epilepsy.

2014

This study aimed at providing an insight on the possible role of cannabi-noid (CB) type 2 receptors (CB2R) and cGMP pathway in the antiepileptic activity ofWIN 55,212-2, (R)-(+)-[2,3-dihydro-5-methyl-3-(4-morpholinylmethyl) pyrrolo[1,2,3-de]-1,4-benzoxazin-6-Yl]-1-naphthalenylmethanone, a non-selective CB agonist, in the maximal dentate activation (MDA) model of partial epilepsy in adult male rats. We evaluated the activity of a CB2 antagonist/inverse agonist AM630, [6-iodo-2-methyl-1-[2-(4-morpholinyl)ethyl]-1H-indol-3-yl](4-methoxyphenyl)methanone or 6-iodopravadoline, alone or in co-administration with WIN 55,212-2. Also, in the MDA model it was investigated the co-treatment of WIN55,212…

AgonistMaleIndolessGCmedicine.drug_classmedicine.medical_treatmentMorpholinesPharmacologyNaphthalenesSettore BIO/09 - FisiologiaHippocampusNitric oxideReceptor Cannabinoid CB2chemistry.chemical_compoundHippocampumedicineCannabinoid receptor type 2Inverse agonistAnimalsRats WistarReceptorCannabinoidCannabinoid Receptor AntagonistsCyclic GMPCannabinoid Receptor AgonistsElectrophysiology.ChemistryAntagonistElectric StimulationBenzoxazinesDisease Models AnimalNeurologyGuanylate CyclaseAnticonvulsantsNeurology (clinical)CannabinoidEpilepsies PartialSoluble guanylyl cyclaseTemporal Lobe Epilepsy AM630Epilepsy research
researchProduct

WIN55,212-2, a cannabinoid receptor agonist, protects against nigrostriatal cell loss in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model…

2009

Parkinson's disease (PD) is characterized by the progressive loss of nigrostriatal dopamine neurons leading to motor disturbances and cognitive impairment. Current pharmacotherapies relieve PD symptoms temporarily but fail to prevent or slow down the disease progression. In this study, we investigated the molecular mechanisms by which the non-selective cannabinoid receptor agonist WIN55,212-2 (WIN) protects mouse nigrostriatal neurons from 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced neurotoxicity and neuroinflammation. Stereological analyses showed that chronic treatment with WIN (4 mg/kg, intraperitoneal), initiated 24 h after MPTP administration, protected against MPTP-ind…

Agonistmedicine.drug_classbusiness.industryPars compactaGeneral NeuroscienceMPTPCannabinoid Receptor AgonistsSubstantia nigraPharmacologynervous system diseaseschemistry.chemical_compoundnervous systemchemistryDopaminemedicineCannabinoid receptor type 2MPTP Poisoninglipids (amino acids peptides and proteins)businessmedicine.drugEuropean Journal of Neuroscience
researchProduct

Manejo de la hiperglucemia con fármacos no insulínicos en pacientes adultos con diabetes tipo 2

2019

Resumen: El adecuado tratamiento de la diabetes mellitus tipo 2 (DM2) incluye la alimentación saludable y el ejercicio (150 min/semana) como pilares básicos. Para el tratamiento farmacológico, la metformina es el fármaco de elección inicial, salvo contraindicación o intolerancia; en caso de mal control, se dispone de 8 familias terapéuticas (6 orales y 2 inyectables) como posibles combinaciones. Se presenta un algoritmo y unas recomendaciones para el tratamiento de la DM2. En prevención secundaria cardiovascular se recomienda asociar un inhibidor del cotransportador sodio-glucosa tipo 2 (iSGLT2) o un agonista del receptor de glucagon-like peptide-1 (arGLP1) en pacientes con obesidad. En pre…

Agonistmedicine.medical_specialtymedicine.drug_class030204 cardiovascular system & hematologyOverweight:Phenomena and Processes::Physiological Phenomena::Nutritional Physiological Phenomena::Diet::Diabetic Diet [Medical Subject Headings]GastroenterologyDiabetes tipo 2:Organisms::Eukaryota::Animals::Chordata::Vertebrates::Mammals::Primates::Haplorhini::Catarrhini::Hominidae::Humans [Medical Subject Headings]03 medical and health sciences0302 clinical medicineFármacos antidiabéticos:Diseases::Nutritional and Metabolic Diseases::Metabolic Diseases::Glucose Metabolism Disorders::Hyperglycemia [Medical Subject Headings]Internal medicineDiabetes mellitusmedicineGliclazide030212 general & internal medicineHiperglucemiaContraindicationlcsh:R5-920business.industryAntidiabetic drugs:Diseases::Endocrine System Diseases::Diabetes Mellitus::Diabetes Mellitus Type 2 [Medical Subject Headings]nutritional and metabolic diseases:Psychiatry and Psychology::Behavior and Behavior Mechanisms::Psychology Social::Life Style [Medical Subject Headings]Type 2 diabetesGeneral Medicinemedicine.diseaseSulfonylureaObesityHumanos:Diseases::Nutritional and Metabolic Diseases::Nutrition Disorders::Overnutrition::Obesity [Medical Subject Headings]MetforminHyperglycemia:Chemicals and Drugs::Chemical Actions and Uses::Pharmacologic Actions::Physiological Effects of Drugs::Hypoglycemic Agents [Medical Subject Headings]medicine.symptomlcsh:Medicine (General)Family Practicebusinessmedicine.drug
researchProduct

Metabolic impact of adult-onset, isolated, growth hormone deficiency (AOiGHD) due to destruction of pituitary somatotropes.

2011

Growth hormone (GH) inhibits fat accumulation and promotes protein accretion, therefore the fall in GH observed with weight gain and normal aging may contribute to metabolic dysfunction. To directly test this hypothesis a novel mouse model of adult onset-isolated GH deficiency (AOiGHD) was generated by cross breeding rat GH promoter-driven Cre recombinase mice (Cre) with inducible diphtheria toxin receptor mice (iDTR) and treating adult Cre(+/-), iDTR(+/-) offspring with DT to selectively destroy the somatotrope population of the anterior pituitary gland, leading to a reduction in circulating GH and IGF-I levels. DT-treated Cre(-/-), iDTR(+/-) mice were used as GH-intact controls. AOiGHD im…

Anatomy and PhysiologyMousemedicine.medical_treatmentgh deficiencyMiceEndocrinology0302 clinical medicinefactor-iInsulinglucoseAge of OnsetInsulin-Like Growth Factor I2. Zero hunger0303 health scienceseducation.field_of_studyMultidisciplinarypancreatic beta-cellQRAnimal ModelsGHreceptor genehypothalamic expressionmedicine.anatomical_structureCarbohydrate MetabolismIntercellular Signaling Peptides and ProteinsMedicineincreased insulin sensitivityResearch ArticleHeparin-binding EGF-like Growth Factormedicine.medical_specialtymicediet-induced obesityDisfunción metabólicaSomatotropic cellSciencePopulationEndocrine System030209 endocrinology & metabolismBiologyCarbohydrate metabolismGrowth hormone deficiency03 medical and health sciencesModel OrganismsInsulin resistanceAnterior pituitaryreplacement therapyPituitary Gland AnteriorGrowth FactorsInternal medicinemedicineAnimalsObesityeducationBiologyNutrition030304 developmental biologyDiabetic EndocrinologyEndocrine PhysiologyInsulinDiabetes Mellitus Type 2Metabolyc disfunctionmedicine.diseaseHormonesMice Mutant StrainsSomatotrophsProlactinDietRatsDisease Models AnimalEndocrinologyPituitaryGrowth HormoneInsulin ResistanceEnergy IntakeEnergy MetabolismGHDPLoS ONE
researchProduct

Coffee components and cardiovascular risk: beneficial and detrimental effects

2014

Coffee consists of several biological active compounds, such as caffeine, diterpenes, chlorogenic acids, and melanoidins, which may affect human health. The intake of each compound depends on the variety of coffee species, roasting degree, type of brewing method and serving size. The bioavailability and the distribution of each compound and its metabolites also contribute to coffee mechanisms of action. The health benefits of coffee consumption regarding cardiovascular system and metabolism mostly depend on its antioxidant compounds. In contrast, diterpenes and caffeine may produce harmful effects by raising lipid fraction and affecting endothelial function, respectively. Studying the mecha…

AntioxidantSettore MED/09 - Medicina InternaPolymersmedicine.medical_treatmentLipid fractionCoffee consumptionBiologyHealth benefitsCardiovascular SystemCoffeeHuman healthchemistry.chemical_compoundAlkaloidsCaffeinemedicineHumansFood scienceSettore MED/49 - Scienze Tecniche Dietetiche ApplicatePlant ExtractsPolyphenolscoffee cardiovascular riskDiabetes Mellitus Type 2chemistryCardiovascular DiseasesChlorogenic AcidDiterpenesCaffeineFood Science
researchProduct

Prophylaxis of Non-communicable Diseases: Why fruits and vegetables may be better chemopreventive agents than dietary supplements based on isolated p…

2019

The World Health Organization (WHO) report from 2014 documented that non-communicable socalled civilization diseases such as cardiovascular disease, chronic respiratory diseases, cancer or type 2 diabetes are responsible for over 50% of all premature deaths in the world. Research carried out over the past 20 years has provided data suggesting that diet is an essential factor influencing the risk of development of these diseases. The increasing knowledge on chemopreventive properties of certain food ingredients, in particular, those of plant origin, opened the discussion on the possibility to use edible plants or their active components in the prevention of these chronic diseases. Health-pro…

Antioxidants; Bioactive phytochemicals; Cancer; Chemoprevention; Civilization diseases; Flavonoids; Food synergyantioxidantPhytochemicalsRespiratory Tract DiseasesActive componentsDiseaseChemopreventionWorld healthAntioxidants03 medical and health sciencesbioactive phytochemical0302 clinical medicineFunctional foodNeoplasmsVegetablesDrug DiscoveryHumansMedicinecivilization diseaseflavonoidNoncommunicable Diseases030304 developmental biologyCancer2. Zero hungerPharmacologyFlavonoids0303 health sciencesTraditional medicineFood synergyHuman organismbusiness.industryBioactive phytochemicalsDiet3. Good healthDiabetes Mellitus Type 2Cardiovascular DiseasesFruit030220 oncology & carcinogenesisFruits and vegetablesDietary SupplementsEdible plantsCivilization diseasesCritical assessmentbusiness
researchProduct

Influence of the metabolic syndrome on aortic stiffness in never treated hypertensive patients

2004

Summary Background and aim Metabolic syndrome (MS) carries an increased risk for cardiovascular events and there is a growing awareness that large artery stiffening is a powerful predictor of cardiovascular morbidity and mortality. Little is known about the relationship of MS with aortic stiffness. The aim of our study was to analyze, in patients with essential hypertension, the influence of MS, defined according to the criteria proposed by the Third Report of the National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (NCEP-ATP III), on carotid–femoral pulse wave velocity (PWV), a measure of aortic stiffness. Methods N…

Arterial hypertensionAdultMalemedicine.medical_specialtySettore MED/09 - Medicina InternaAmbulatory blood pressureEndocrinology Diabetes and MetabolismMedicine (miscellaneous)Essential hypertensionRisk FactorsInternal medicineDiabetes mellitusmedicineAlbuminuriaHumansPulse wave velocityNational Cholesterol Education ProgramAortaMetabolic SyndromeNutrition and Dieteticsbusiness.industryAge FactorsBlood Pressure Monitoring AmbulatoryMiddle AgedCardiovascular riskmedicine.diseaseSettore MED/11 - Malattie Dell'Apparato CardiovascolareElasticityFemoral ArteryPulse wave velocityAortic stiffneCarotid ArteriesBlood pressureEndocrinologyDiabetes Mellitus Type 2Blood chemistryCase-Control StudiesHypertensionCardiologyRegression AnalysisFemaleMetabolic syndromeCardiology and Cardiovascular MedicinebusinessNutrition, Metabolism and Cardiovascular Diseases
researchProduct